CRL · 8-K · 20260805PR000115

Revenue Performance and Mix

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 24 · Surprise 14 · No source text

Second-quarter revenue was $1.004 billion, down 2.7% year over year from $1.032 billion, while organic revenue increased 0.1%. Manufacturing Solutions revenue was $188.1 million, down 6.3% due primarily to the CDMO divestiture, although organic revenue increased 1.3% on higher Microbial Solutions revenue. Discovery and Safety Assessment revenue was $606.5 million, down 1.9% reported but up 0.2% organically on higher regulated safety-assessment study volume. Research Models and Services revenue was $209.5 million, down 1.8% reported and 1.4% organically, primarily because of lower small research-model and research-model-services revenue in North America, partly offset by higher small-model revenue in China.

Key facts

• Second-quarter revenue: $1.00 billion for the quarter ended June 27, 2026. source
• Total revenue decreased 2.7% versus the second quarter of 2025 (from $1.03 billion to $1.00 billion). source
• Company reported GAAP net loss available to common shareholders for Q2 2026: $(1.5) million, or $(0.03) per diluted share, versus GAAP net income of $52.3 million, or $1.06 per diluted share in Q2 2025. source
• DSA segment revenue for Q2 2026: $606.5 million, a decrease of 1.9% from $618.0 million in Q2 2025. source
• Manufacturing segment revenue for Q2 2026: $188.1 million, a decrease of 6.3% from $200.8 million in Q2 2025, primarily driven by the CDMO divestiture. source
• RMS segment revenue for Q2 2026: $209.5 million, down 1.8% from $213.3 million in Q2 2025. source
• Non-GAAP earnings per share for the second quarter: $3.02. source
• Organic revenue growth for the second quarter: 0.1%. source

Impact estimates